China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totaling 44,700 shares, a decline of 40.6% from the August 15th total of 75,200 shares. Approximately 0.0% of the company's stock are sold short. Based on an average trading volume of 308,800 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 308,800 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd.
Check Out Our Latest Stock Report on China SXT Pharmaceuticals
China SXT Pharmaceuticals Stock Up 2.6%
SXTC traded up $0.05 during trading on Friday, hitting $1.95. 209,088 shares of the company traded hands, compared to its average volume of 1,694,511. The stock's fifty day moving average is $1.61 and its 200 day moving average is $1.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 3.40. China SXT Pharmaceuticals has a one year low of $0.95 and a one year high of $7.84.
About China SXT Pharmaceuticals
(
Get Free Report)
China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Further Reading
Before you consider China SXT Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.
While China SXT Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.